{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:38:43Z","timestamp":1760121523853,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.revmed.2007.06.008","type":"journal-article","created":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T07:12:52Z","timestamp":1182928372000},"page":"852-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bioth\u00e9rapies et\u00a0MICI : anti-TNF et\u00a0nouvelles cibles th\u00e9rapeutiques"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Flamant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bourreille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2007.06.008_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.2003.50045","article-title":"The genetics of inflammatory bowel disease","volume":"124","author":"Bonen","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1132","article-title":"The immunological and genetic basis of inflammatory bowel disease","volume":"3","author":"Bouma","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.revmed.2007.06.008_bib3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.172.6.1701","article-title":"OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset","volume":"172","author":"Powrie","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1084\/jem.179.2.589","article-title":"Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity","volume":"179","author":"Powrie","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","article-title":"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis","volume":"389","author":"Groux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2007.06.008_bib6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.revmed.2007.06.008_bib7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.revmed.2007.06.008_bib8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/gut.47.3.397","article-title":"Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease","volume":"47","author":"Segain","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT-1 randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2007.06.008_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib15","first-page":"429","article-title":"Groupe Recherche Anti-TNF et Infections Opportunistes; Agence francaise de s\u00e9curite sanitaire des produits de sant\u00e9. Recommendations for the prevention and management of tuberculosis in patients taking infliximab","volume":"153","author":"Salmon-Ceron","year":"2002","journal-title":"Ann. Med. Interne (Paris)"},{"issue":"suppl.2","key":"10.1016\/j.revmed.2007.06.008_bib16","first-page":"A178","article-title":"Safety of Infliximab and other Crohn\u2019s disease therapies \u2014 treat\u2122 Registry data with nearly 20\u00a0000 patients-years of follow-up","volume":"132","author":"Lichtenstein","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib18","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2007.06.008_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.revmed.2007.06.008_bib20","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.revmed.2007.06.008_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2007.06.008_bib23","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2007.06.008_bib24","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2007.06.008_bib25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1572-0241.2004.40462.x","article-title":"An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease","volume":"99","author":"Sandborn","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"suppl. 5","key":"10.1016\/j.revmed.2007.06.008_bib26","first-page":"A20","article-title":"Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the gain study","volume":"55","author":"Rutgeerts","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for Maintenance Treatment of Crohn's disease: results of the CLASSIC-2 Trial","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"suppl 2","key":"10.1016\/j.revmed.2007.06.008_bib30","first-page":"A107","article-title":"Certolizumab Pegol administred subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECISE-1)","volume":"130","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib31","first-page":"A82","article-title":"Certolizumab pegol, a humanized anti-TNF-\u03b1 pegylated Fab fragment is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECISE)","volume":"54","author":"Schreiber","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib36","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2005.083121","article-title":"Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine\u2013anticytokine strategies the future for IBD therapies?","volume":"55","author":"Pizarro","year":"2006","journal-title":"Gut"},{"issue":"Suppl 16","key":"10.1016\/j.revmed.2007.06.008_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02990576","article-title":"Treatment of Crohn's disease with anti-IL-6 receptor antibody","volume":"40","author":"Ito","year":"2005","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.revmed.2007.06.008_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"Kuhn","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.revmed.2007.06.008_bib39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of human recombinant interleukin 10 in active Crohn's disease","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.49.1.42","article-title":"Interleukin 10 (tenovil) in the prevention of postoperative recurrence of Crohn's disease","volume":"49","author":"Colombel","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease","volume":"4","author":"Braat","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.revmed.2007.06.008_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","article-title":"Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease","volume":"117","author":"Sands","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib43","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"suppl 2","key":"10.1016\/j.revmed.2007.06.008_bib44","first-page":"A72","article-title":"A safety evaluation for progressive multifocal leucoencephalopathy in greater than 3500 patients with Crohn's disease (CD), multiple sclerosis, and rheumatoid arthritis previously treated by natalizumab in clinical trials","volume":"130","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib45","doi-asserted-by":"crossref","first-page":"A178","DOI":"10.1016\/S0016-5085(03)80125-7","article-title":"Efficacy and safety of a humanized \u03b14\u03b27 antibody in active Crohn's disease (CD)","volume":"124","author":"Feagan","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib46","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib47","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.2001.24015","article-title":"Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease","volume":"120","author":"Schreiber","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/gut.51.1.30","article-title":"Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease","volume":"51","author":"Yacyshyn","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib49","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1046\/j.1365-2036.2002.01341.x","article-title":"Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease","volume":"16","author":"Yacyshyn","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib50","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1365-2036.2006.02837.x","article-title":"Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial","volume":"23","author":"Miner","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib51","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"S2","key":"10.1016\/j.revmed.2007.06.008_bib52","first-page":"A51","article-title":"A multicenter, randomized, Phase IIa Study of Human Monoclonal Antibody to IL-12\/23p40 (Cnto 1275) in patients with moderately to severely active Crohn's disease","volume":"130","author":"Sandborn","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib53","first-page":"A505","article-title":"Preliminary results of a phase I\u2013II study of Huzaf, an anti IFN-\u03b3 monoclonal antibody, in patients with moderate to severe active Crohn's disease","volume":"122","author":"Rutgeerts","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib54","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.2005.079392","article-title":"Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease","volume":"55","author":"Hommes","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2007.06.008_bib55","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim for active Crohn's disease","volume":"352","author":"Korzenik","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"S2","key":"10.1016\/j.revmed.2007.06.008_bib56","first-page":"A502","article-title":"Sargramostim induces steroid free remission in corticoid-dependent Crohn's disease: results of NOVEL-2, a phase II muticenter study","volume":"132","author":"Valentine","year":"2007","journal-title":"Gastroenterology"},{"issue":"S2","key":"10.1016\/j.revmed.2007.06.008_bib57","first-page":"A103","article-title":"Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of NOVEL-4, a phase III Multicenter study","volume":"132","author":"Feagan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib58","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2001.04039.x","article-title":"Infliximab for refractory ulcerative colitis","volume":"96","author":"Chey","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.revmed.2007.06.008_bib59","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","article-title":"Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis","volume":"97","author":"Su","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.revmed.2007.06.008_bib60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1590-8658(02)80205-5","article-title":"Infliximab for treatment of steroid-refractory ulcerative colitis","volume":"34","author":"Actis","year":"2002","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.revmed.2007.06.008_bib61","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"issue":"353","key":"10.1016\/j.revmed.2007.06.008_bib62","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"8","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib63","first-page":"A579","article-title":"A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study","volume":"126","author":"Plevy","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib64","first-page":"A493","article-title":"A phase I study: multiple dose levels visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids","volume":"128","author":"Targan","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2007.06.008_bib65","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha 4 beta 7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2007.06.008_bib66","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-2036.2006.02910.x","article-title":"A phase II dose ranging, double blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis","volume":"23","author":"Van Deventer","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib67","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1365-2036.2006.02837.x","article-title":"Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double blind, active-controlled trial","volume":"23","author":"Miner","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib68","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gut.2005.089854","article-title":"Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial","volume":"55","author":"Van Assche","year":"2006","journal-title":"Gut"},{"issue":"23","key":"10.1016\/j.revmed.2007.06.008_bib69","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1365-2036.2006.02904.x","article-title":"Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease","volume":"15","author":"Creed","year":"2006","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.revmed.2007.06.008_bib70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.MIB.0000172807.26748.16","article-title":"RDP58 is a novel and potentially effective oral therapy for ulcerative colitis","volume":"11","author":"Travis","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.revmed.2007.06.008_bib71","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"issue":"suppl.2","key":"10.1016\/j.revmed.2007.06.008_bib72","first-page":"A110","article-title":"A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease","volume":"128","author":"D'Haens","year":"2006","journal-title":"Gastroenterology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630700625X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630700625X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:21:06Z","timestamp":1759335666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886630700625X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S024886630700625X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2007.06.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioth\u00e9rapies et\u00a0MICI: anti-TNF et\u00a0nouvelles cibles th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2007.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}